Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate

Nicolino Ruperto, Angelo Ravelli, Fernanda Falcini, Loredana Lepore, Rosetta De Sanctis, Francesco Zulian, Antonella Buoncompagni, Maria Luisa Sardella, Ciro Strano, Maria Alessio, Stefania Viola, Alberto Martini

Research output: Contribution to journalArticle

Abstract

Objective - To investigate the performance of the core set of outcome measures and the preliminary definition of improvement (PDI) in the assessment of response to methotrexate (MTX) treatment in children with juvenile chronic arthritis (JCA). Methods - Data were obtained from an open label, non-controlled trial designed to investigate the efficacy of MTX in children with JCA. All patients had the core set of variables assessed at baseline and after six months of treatment. Variables in the core set are: (1) physician global assessment of disease activity; (2) parent or patient (if appropriate in age) global assessment of overall well being; (3) functional ability; (4) number of joints with active arthritis; (5) number of joints with limited range of motion; (6) erythrocyte sedimentation rate. The PDI specifies that to be classified as improved, a patient must show at least 30% improvement from baseline in three of any six variables in the core set, with no more than one of the remaining variables worsening by more than 30%. Results - A total of 111 JCA patients were included in the study. According to the PDI, after six months of MTX treatment 73 patients (66%) were classified as improved and 38 (34%) as not improved. Among the core set variables, parent assessment detected the highest percentage of patients improved (72%) and functional assessment the lowest (37%). Conclusion - The PDI identifies about two thirds of patients with JCA treated with low dose MTX as improved. This proportion is similar to that expected to improve based upon a previous controlled study of low dose, oral MTX and provides preliminary evidence of the definition's validity.

Original languageEnglish
Pages (from-to)38-41
Number of pages4
JournalAnnals of the Rheumatic Diseases
Volume57
Issue number1
Publication statusPublished - 1998

Fingerprint

Juvenile Arthritis
Methotrexate
Functional assessment
Patient treatment
Joints
Sedimentation
Labels
Blood Sedimentation
Articular Range of Motion
Arthritis
Therapeutics
Outcome Assessment (Health Care)
Physicians

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. / Ruperto, Nicolino; Ravelli, Angelo; Falcini, Fernanda; Lepore, Loredana; De Sanctis, Rosetta; Zulian, Francesco; Buoncompagni, Antonella; Sardella, Maria Luisa; Strano, Ciro; Alessio, Maria; Viola, Stefania; Martini, Alberto.

In: Annals of the Rheumatic Diseases, Vol. 57, No. 1, 1998, p. 38-41.

Research output: Contribution to journalArticle

Ruperto, N, Ravelli, A, Falcini, F, Lepore, L, De Sanctis, R, Zulian, F, Buoncompagni, A, Sardella, ML, Strano, C, Alessio, M, Viola, S & Martini, A 1998, 'Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate', Annals of the Rheumatic Diseases, vol. 57, no. 1, pp. 38-41.
Ruperto, Nicolino ; Ravelli, Angelo ; Falcini, Fernanda ; Lepore, Loredana ; De Sanctis, Rosetta ; Zulian, Francesco ; Buoncompagni, Antonella ; Sardella, Maria Luisa ; Strano, Ciro ; Alessio, Maria ; Viola, Stefania ; Martini, Alberto. / Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. In: Annals of the Rheumatic Diseases. 1998 ; Vol. 57, No. 1. pp. 38-41.
@article{d804cb8ca4fe426ba974a853e8abbfa5,
title = "Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate",
abstract = "Objective - To investigate the performance of the core set of outcome measures and the preliminary definition of improvement (PDI) in the assessment of response to methotrexate (MTX) treatment in children with juvenile chronic arthritis (JCA). Methods - Data were obtained from an open label, non-controlled trial designed to investigate the efficacy of MTX in children with JCA. All patients had the core set of variables assessed at baseline and after six months of treatment. Variables in the core set are: (1) physician global assessment of disease activity; (2) parent or patient (if appropriate in age) global assessment of overall well being; (3) functional ability; (4) number of joints with active arthritis; (5) number of joints with limited range of motion; (6) erythrocyte sedimentation rate. The PDI specifies that to be classified as improved, a patient must show at least 30{\%} improvement from baseline in three of any six variables in the core set, with no more than one of the remaining variables worsening by more than 30{\%}. Results - A total of 111 JCA patients were included in the study. According to the PDI, after six months of MTX treatment 73 patients (66{\%}) were classified as improved and 38 (34{\%}) as not improved. Among the core set variables, parent assessment detected the highest percentage of patients improved (72{\%}) and functional assessment the lowest (37{\%}). Conclusion - The PDI identifies about two thirds of patients with JCA treated with low dose MTX as improved. This proportion is similar to that expected to improve based upon a previous controlled study of low dose, oral MTX and provides preliminary evidence of the definition's validity.",
author = "Nicolino Ruperto and Angelo Ravelli and Fernanda Falcini and Loredana Lepore and {De Sanctis}, Rosetta and Francesco Zulian and Antonella Buoncompagni and Sardella, {Maria Luisa} and Ciro Strano and Maria Alessio and Stefania Viola and Alberto Martini",
year = "1998",
language = "English",
volume = "57",
pages = "38--41",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate

AU - Ruperto, Nicolino

AU - Ravelli, Angelo

AU - Falcini, Fernanda

AU - Lepore, Loredana

AU - De Sanctis, Rosetta

AU - Zulian, Francesco

AU - Buoncompagni, Antonella

AU - Sardella, Maria Luisa

AU - Strano, Ciro

AU - Alessio, Maria

AU - Viola, Stefania

AU - Martini, Alberto

PY - 1998

Y1 - 1998

N2 - Objective - To investigate the performance of the core set of outcome measures and the preliminary definition of improvement (PDI) in the assessment of response to methotrexate (MTX) treatment in children with juvenile chronic arthritis (JCA). Methods - Data were obtained from an open label, non-controlled trial designed to investigate the efficacy of MTX in children with JCA. All patients had the core set of variables assessed at baseline and after six months of treatment. Variables in the core set are: (1) physician global assessment of disease activity; (2) parent or patient (if appropriate in age) global assessment of overall well being; (3) functional ability; (4) number of joints with active arthritis; (5) number of joints with limited range of motion; (6) erythrocyte sedimentation rate. The PDI specifies that to be classified as improved, a patient must show at least 30% improvement from baseline in three of any six variables in the core set, with no more than one of the remaining variables worsening by more than 30%. Results - A total of 111 JCA patients were included in the study. According to the PDI, after six months of MTX treatment 73 patients (66%) were classified as improved and 38 (34%) as not improved. Among the core set variables, parent assessment detected the highest percentage of patients improved (72%) and functional assessment the lowest (37%). Conclusion - The PDI identifies about two thirds of patients with JCA treated with low dose MTX as improved. This proportion is similar to that expected to improve based upon a previous controlled study of low dose, oral MTX and provides preliminary evidence of the definition's validity.

AB - Objective - To investigate the performance of the core set of outcome measures and the preliminary definition of improvement (PDI) in the assessment of response to methotrexate (MTX) treatment in children with juvenile chronic arthritis (JCA). Methods - Data were obtained from an open label, non-controlled trial designed to investigate the efficacy of MTX in children with JCA. All patients had the core set of variables assessed at baseline and after six months of treatment. Variables in the core set are: (1) physician global assessment of disease activity; (2) parent or patient (if appropriate in age) global assessment of overall well being; (3) functional ability; (4) number of joints with active arthritis; (5) number of joints with limited range of motion; (6) erythrocyte sedimentation rate. The PDI specifies that to be classified as improved, a patient must show at least 30% improvement from baseline in three of any six variables in the core set, with no more than one of the remaining variables worsening by more than 30%. Results - A total of 111 JCA patients were included in the study. According to the PDI, after six months of MTX treatment 73 patients (66%) were classified as improved and 38 (34%) as not improved. Among the core set variables, parent assessment detected the highest percentage of patients improved (72%) and functional assessment the lowest (37%). Conclusion - The PDI identifies about two thirds of patients with JCA treated with low dose MTX as improved. This proportion is similar to that expected to improve based upon a previous controlled study of low dose, oral MTX and provides preliminary evidence of the definition's validity.

UR - http://www.scopus.com/inward/record.url?scp=15444352940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444352940&partnerID=8YFLogxK

M3 - Article

C2 - 9536821

AN - SCOPUS:15444352940

VL - 57

SP - 38

EP - 41

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -